Cystatin C

Onopiuk, Anna; Tokarzewicz, Anna; Gorodkiewicz, Ewa

doi:10.1016/bs.acc.2014.11.007

Cited by 130 publications

(53 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increases in blood urea nitrogen were not observed (Supplemental Figure 3). A post hoc analysis of baseline and Day 15 cystatin C, an alternative marker of renal function independent of serum creatinine used to estimate glomerular filtration rate (GFR) 27,28 , demonstrated that the rise in serum creatinine was not associated with elevation in cystatin C, and cystatin C-calculated GFR was not reduced; thus, the rise in serum creatinine was not temporally associated with reduced renal function (Supplemental Figure 4 and data not shown). …”

Section: Resultsmentioning

confidence: 99%

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Dickler

Tolaney

Rugo

et al. 2017

Clinical Cancer Research

549

494

View full text Add to dashboard Cite

Purpose The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2− metastatic breast cancer (MBC). Experimental Design MONARCH 1 was a phase 2 single arm open-label study. Women with HR+/HER2− MBC who had progressed on or after prior endocrine therapy and had 1 or 2 chemotherapy regimens in the metastatic setting were eligible. Abemaciclib 200 mg was administered orally on a continuous schedule every 12 hours until disease progression or unacceptable toxicity. The primary objective of MONARCH 1 was investigator-assessed objective response rate (ORR). Other endpoints included clinical benefit rate, progression-free survival (PFS) and overall survival (OS). Results Patients (n=132) had a median of 3 (range 1–8) lines of prior systemic therapy in the metastatic setting, 90.2% had visceral disease, and 50.8% had ≥3 metastatic sites. At the 12 month final analysis, the primary objective of confirmed objective response rate was 19.7% (95% CI: 13.3, 27.5; 15% not excluded); clinical benefit rate (CR+PR+SD≥6 months) was 42.4%, median progression-free survival was 6.0 months, and median overall survival was 17.7 months. The most common treatment-emergent AEs of any grade were diarrhea, fatigue, and nausea; discontinuations due to AEs were infrequent (7.6%). Conclusion In this poor-prognosis, heavily pre-treated population with refractory HR+/HER2- metastatic breast cancer, continuous dosing of single agent abemaciciclib was well tolerated and exhibited promising clinical activity.

show abstract

Section: Resultsmentioning

confidence: 99%

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Dickler

Tolaney

Rugo

et al. 2017

Clinical Cancer Research

549

494

View full text Add to dashboard Cite

show abstract

“…Second, we applied GFR values estimated through measurement of plasma cystatin-C to evaluate the effect of TDF use on short-term renal function in HIV-infected individuals. Currently, eGFR by cystatin-C is considered the most precise biomarker of creatinine clearance evaluating renal function and the most sensitive method that can predict early mild renal impairment 2336. Another advantage of eGFR by cystatin-C is that this measurement is not affected by anthropometric variables of age or sex or by muscle weight, which could differ based on race or lifestyle, such as diet, or diseases, such as chronic exhausting infectious diseases, including HIV infection 233637.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, eGFR by cystatin-C is considered the most precise biomarker of creatinine clearance evaluating renal function and the most sensitive method that can predict early mild renal impairment 2336. Another advantage of eGFR by cystatin-C is that this measurement is not affected by anthropometric variables of age or sex or by muscle weight, which could differ based on race or lifestyle, such as diet, or diseases, such as chronic exhausting infectious diseases, including HIV infection 233637. Also, eGFR by cystatin-C is a useful biomarker, especially in proximal tubular injury, because plasma cystatin-C is initially filtered at the glomerulus and reabsorbed by epithelial cells of the proximal tubule, with only small amounts excreted into urine 3839.…”

Section: Discussionmentioning

confidence: 99%

“…The detailed equations are as follows: 1) eGFR (MDRD)=175×(SCr) −1.154 ×(age) −0.203 ×(0.742 if female),26 2) eGFR (CKD-EPI)=141×minimum (SCr/κ or 1) α ×maximum (SCr/κ or 1) −1.209 ×0.993 age ×(1.018 if female), (κ=0.9 if male, 0.7 if female and α=−0.411 if male, −0.329 if female),23 and 3) eGFR (cystatin-C) (Larsson formula)=77.239×cystatin C −1.2623 2327…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study

Lee

et al. 2017

Yonsei Med J

View full text Add to dashboard Cite

PurposeTenofovir disoproxil fumarate (TDF) is commonly prescribed as a fixed-dose, co-formulated antiretroviral drug for HIV-1 infection. The major concern of long-term TDF use is renal dysfunction. However, little is known about the long-term patterns of changes in renal function in HIV-infected Koreans receiving TDF.Materials and MethodsWe prospectively followed 50 HIV-infected Koreans, performing laboratory tests every 3 months during the first year and every 6 months for the next 2 years. Urine N-acetyl-β-D-glucosaminidase (NAG) and plasma cystatin-C were measured using samples collected in the first year. Data on renal function were retrospectively collected on HIV-infected patients receiving first-line TDF (n=40) and in antiretroviral therapy (ART)-naïve patients (n=24) for 3 years. Renal function was evaluated as estimated glomerular filtration rate (eGFR) from serum creatinine [Modification of Diet in Renal Disease (MDRD)] and cystatin-C.ResultsThe eGFR (cystatin-C) showed significant changes from 0 to 48 wks (p=0.002), with the lowest levels at 24 wks (84.3±18.8 mL/min vs. 90.3±22.5 mL/min, p=0.021 by post hoc test). Urine NAG levels did not differ at 0, 12, 24, and 48 wks, although eGFR (MDRD) significantly decreased from 0 (98.7±18.9 mL/min/1.73 m2) to 144 wks (89.0±14.7 mL/min/1.73 m2) (p=0.010). The first-line TDF group had significantly lower eGFR (MDRD) than the ART-naïve group at 144 wks (89.7 mL/min/1.73 m2 vs. 98.4 mL/min/1.73 m2, p=0.036). Thirteen (26%) participants experienced a decrease in renal impairment of 10 mL/min/1.73 m2 in eGFR (MDRD) at 144 wks.ConclusionThese data suggest that clinically meaningful renal injury can develop in HIV-infected Koreans receiving long-term TDF.

show abstract

“…Biosensors are also used to detect mercury levels in aquatic animals. In this method, it is possible to detect the amount of mercury and bacteria from this mercury by irradiation [37].Using the biosensors made of gold nanowire, bacteria in the kidney infection can be detected [38]. Biosensors can examine the quality of cereals and detect pathogens in cereals with polymer nanoparticles.…”

Section: Biosensorsmentioning

confidence: 99%

Application of Biomarkers and Biosensors to Detect and Track Pathogenic Agents

Shirzadfar¹,

Khanahmadi²

2018

IJAT

View full text Add to dashboard Cite

Biomarkers are an indicator for measuring and detecting pathogenic factors and assessing biological conditions. Biomarkers in the field of cancer diagnosis and treatment have been widely considered and have been widely used in these fields. Biomarker is an indicator of a specific disease and physical states in the living tissue, and the biomarker can detect the symptoms of a specific disease. Some biomarkers are delivered the drug to the tissue that the biomarker is labeled with that drug and is transmitted to the target tissue. Markers are divided into molecular and phenotypic types, and molecular types are available in both biochemical and DNA [1, 2].

show abstract

Cystatin C

Cited by 130 publications

References 46 publications

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study

Application of Biomarkers and Biosensors to Detect and Track Pathogenic Agents

Contact Info

Product

Resources

About